Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Clasificación en acciones #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Precio por acción
$0.5275
Capitalización bursátil
$1.25M
Cambio (1 día)
-3.56%
Cambio (1 año)
-83.77%
País
US
Comercio Ensysce Biosciences, Inc. (ENSC)

Categoría

Healthcare
Número de acciones en circulación de Ensysce Biosciences, Inc. (ENSC)
Número de acciones en circulación al September 2025: 2.89M
Según los últimos informes financieros y el precio de las acciones de Ensysce Biosciences, Inc., el número actual de acciones en circulación es 2.89M. Al final de December 2023, la empresa tenía 2.26M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Ensysce Biosciences, Inc. (ENSC) desde 2017 hasta 2026
Acciones en circulación al final de cada año
Año Acciones en circulación Cambiar
2026 (TTM) 2.89M 65.20%
2024 1.75M -22.84%
2023 2.26M 1,158.25%
2022 179.93K 114.16%
2021 84.02K -98.12%
2020 4.46M -26.81%
2019 6.09M 1.42%
2018 6.01M 0.37%
2017 5.98M 0.00%
Acciones en circulación de empresas similares o competidores
Empresa Acciones en circulación Diferencia País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 154,015.04%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 8,697.46%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 3,465.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 6,483.27%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 16,655.56%
AU